Melatonin MT1 and MT2 receptor expression in Parkinson's disease
Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms res...
Gespeichert in:
| Veröffentlicht in: | Medical science monitor 2010-02, Vol.16 (2), p.BR61-BR67 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | BR67 |
|---|---|
| container_issue | 2 |
| container_start_page | BR61 |
| container_title | Medical science monitor |
| container_volume | 16 |
| creator | Adi, Nikhil Mash, Deborah C Ali, Yousuf Singer, Carlos Shehadeh, Lina Papapetropoulos, Spyridon |
| description | Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions.
We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects.
PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733802438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733802438</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-9592d055a6f26b8c30d1066a10cc5bf9f6b1a2f0a32264943d1726a690a8bf953</originalsourceid><addsrcrecordid>eNo1j81KxDAURoMgzjj6CpLdrAo3SZM2O2XwD2bQxbgut80tVNukJi3o21twZnUW3-HAd8HWwuQqU4WGFbtO6RNAlgb0FVtJEAKsEGt2f6Aep-A7zw9HwdG7hZJHamicQuT0M0ZKqQueL8o7xq_Op-C3ibsuESa6YZct9oluT9ywj6fH4-4l2789v-4e9tkoBUyZ1VY60BpNK01dNgqcAGNQQNPourWtqQXKFlBJaXKbKycKadBYwHKZtdqw7X93jOF7pjRVQ5ca6nv0FOZUFUqVIHNVLubdyZzrgVw1xm7A-FudT6s_w4NQGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733802438</pqid></control><display><type>article</type><title>Melatonin MT1 and MT2 receptor expression in Parkinson's disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Adi, Nikhil ; Mash, Deborah C ; Ali, Yousuf ; Singer, Carlos ; Shehadeh, Lina ; Papapetropoulos, Spyridon</creator><creatorcontrib>Adi, Nikhil ; Mash, Deborah C ; Ali, Yousuf ; Singer, Carlos ; Shehadeh, Lina ; Papapetropoulos, Spyridon</creatorcontrib><description>Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions.
We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects.
PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls.
The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.</description><identifier>EISSN: 1643-3750</identifier><identifier>PMID: 20110911</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Amygdala - metabolism ; Amygdala - pathology ; Case-Control Studies ; Cohort Studies ; Down-Regulation ; Female ; Humans ; Immunohistochemistry ; Male ; Parkinson Disease - genetics ; Parkinson Disease - metabolism ; Parkinson Disease - pathology ; Receptor, Melatonin, MT1 - genetics ; Receptor, Melatonin, MT1 - metabolism ; Receptor, Melatonin, MT2 - genetics ; Receptor, Melatonin, MT2 - metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Substantia Nigra - metabolism ; Substantia Nigra - pathology</subject><ispartof>Medical science monitor, 2010-02, Vol.16 (2), p.BR61-BR67</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20110911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adi, Nikhil</creatorcontrib><creatorcontrib>Mash, Deborah C</creatorcontrib><creatorcontrib>Ali, Yousuf</creatorcontrib><creatorcontrib>Singer, Carlos</creatorcontrib><creatorcontrib>Shehadeh, Lina</creatorcontrib><creatorcontrib>Papapetropoulos, Spyridon</creatorcontrib><title>Melatonin MT1 and MT2 receptor expression in Parkinson's disease</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions.
We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects.
PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls.
The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amygdala - metabolism</subject><subject>Amygdala - pathology</subject><subject>Case-Control Studies</subject><subject>Cohort Studies</subject><subject>Down-Regulation</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Parkinson Disease - genetics</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - pathology</subject><subject>Receptor, Melatonin, MT1 - genetics</subject><subject>Receptor, Melatonin, MT1 - metabolism</subject><subject>Receptor, Melatonin, MT2 - genetics</subject><subject>Receptor, Melatonin, MT2 - metabolism</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Substantia Nigra - metabolism</subject><subject>Substantia Nigra - pathology</subject><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j81KxDAURoMgzjj6CpLdrAo3SZM2O2XwD2bQxbgut80tVNukJi3o21twZnUW3-HAd8HWwuQqU4WGFbtO6RNAlgb0FVtJEAKsEGt2f6Aep-A7zw9HwdG7hZJHamicQuT0M0ZKqQueL8o7xq_Op-C3ibsuESa6YZct9oluT9ywj6fH4-4l2789v-4e9tkoBUyZ1VY60BpNK01dNgqcAGNQQNPourWtqQXKFlBJaXKbKycKadBYwHKZtdqw7X93jOF7pjRVQ5ca6nv0FOZUFUqVIHNVLubdyZzrgVw1xm7A-FudT6s_w4NQGg</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Adi, Nikhil</creator><creator>Mash, Deborah C</creator><creator>Ali, Yousuf</creator><creator>Singer, Carlos</creator><creator>Shehadeh, Lina</creator><creator>Papapetropoulos, Spyridon</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201002</creationdate><title>Melatonin MT1 and MT2 receptor expression in Parkinson's disease</title><author>Adi, Nikhil ; Mash, Deborah C ; Ali, Yousuf ; Singer, Carlos ; Shehadeh, Lina ; Papapetropoulos, Spyridon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-9592d055a6f26b8c30d1066a10cc5bf9f6b1a2f0a32264943d1726a690a8bf953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amygdala - metabolism</topic><topic>Amygdala - pathology</topic><topic>Case-Control Studies</topic><topic>Cohort Studies</topic><topic>Down-Regulation</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Parkinson Disease - genetics</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - pathology</topic><topic>Receptor, Melatonin, MT1 - genetics</topic><topic>Receptor, Melatonin, MT1 - metabolism</topic><topic>Receptor, Melatonin, MT2 - genetics</topic><topic>Receptor, Melatonin, MT2 - metabolism</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Substantia Nigra - metabolism</topic><topic>Substantia Nigra - pathology</topic><toplevel>online_resources</toplevel><creatorcontrib>Adi, Nikhil</creatorcontrib><creatorcontrib>Mash, Deborah C</creatorcontrib><creatorcontrib>Ali, Yousuf</creatorcontrib><creatorcontrib>Singer, Carlos</creatorcontrib><creatorcontrib>Shehadeh, Lina</creatorcontrib><creatorcontrib>Papapetropoulos, Spyridon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adi, Nikhil</au><au>Mash, Deborah C</au><au>Ali, Yousuf</au><au>Singer, Carlos</au><au>Shehadeh, Lina</au><au>Papapetropoulos, Spyridon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Melatonin MT1 and MT2 receptor expression in Parkinson's disease</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2010-02</date><risdate>2010</risdate><volume>16</volume><issue>2</issue><spage>BR61</spage><epage>BR67</epage><pages>BR61-BR67</pages><eissn>1643-3750</eissn><abstract>Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions.
We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects.
PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls.
The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.</abstract><cop>United States</cop><pmid>20110911</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1643-3750 |
| ispartof | Medical science monitor, 2010-02, Vol.16 (2), p.BR61-BR67 |
| issn | 1643-3750 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733802438 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Aged Aged, 80 and over Amygdala - metabolism Amygdala - pathology Case-Control Studies Cohort Studies Down-Regulation Female Humans Immunohistochemistry Male Parkinson Disease - genetics Parkinson Disease - metabolism Parkinson Disease - pathology Receptor, Melatonin, MT1 - genetics Receptor, Melatonin, MT1 - metabolism Receptor, Melatonin, MT2 - genetics Receptor, Melatonin, MT2 - metabolism Reverse Transcriptase Polymerase Chain Reaction Substantia Nigra - metabolism Substantia Nigra - pathology |
| title | Melatonin MT1 and MT2 receptor expression in Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T21%3A39%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melatonin%20MT1%20and%20MT2%20receptor%20expression%20in%20Parkinson's%20disease&rft.jtitle=Medical%20science%20monitor&rft.au=Adi,%20Nikhil&rft.date=2010-02&rft.volume=16&rft.issue=2&rft.spage=BR61&rft.epage=BR67&rft.pages=BR61-BR67&rft.eissn=1643-3750&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E733802438%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733802438&rft_id=info:pmid/20110911&rfr_iscdi=true |